Page 1

Interim Report 1 July - 30 September 2021 ● Strategy updated to include two products targeting 510 ( k ) -approval Published data from first comparative study and first study with 5 - year follow - up from Episealer® Directed share issue executed , raising SEK 159 million funding until 2025 secured " We are currently seeing high activity across the business with several initiatives ongoing within our commercialisation , clinical activities and product development . As already communicated , we experienced certain COVID - 19 related effects during the quarter that we cannot disregard , but all in all we are taking important steps in the right direction , as we continuously are adding new customers , geographies , products and data , and we have secured funding until mid - 2025 " , says Pål Ryfors , CEO Episurf Medical . Episealer® Knee Europe & RoW Episealer Knee US Episealer® Talus Europe & RoW Episealer® Patellofemoral System US Episealer® MTP System US H2 2021 Increased commercial focus based on available data 2022 510 ( k ) -filing Concept developmt . Patient recruitment Product launch and initial Episealer® Talus studies Commercialisation 510 ( k ) -approval followed by product launch 510 ( k ) filing late 2022-23 Third quarter 2021 compared to 2020 , Group >>> Gross order intake amounted to SEK 1.6m ( 1.8 ) . >>> Order book amounted to SEK 1.4m ( 1.6 ) >>> Group net sales SEK 1.5m ( 1.5 ) Loss for the period amounted to SEK -15.9m ( -15.4 ) Earnings per share amounted to SEK -0.07 ( -0.08 ) First nine months 2021 compared to 2020 , Group 2023 Patient follow - up Product launch >>> Gross order intake amounted to SEK 5.2m ( 4.3 ) an increase of 21 % >> Group net sales increased by 46 % to SEK 5.1m ( 3.5 ) >>> Loss for the period amounted to SEK -50.4m ( -47.7 ) >>> Earnings per share amounted to SEK -0.23 ( -0.32 ) EPISURF Medical 2024 2025 PMA process Market Opportunity Significant events after the third quarter Episurf Medical carries out a directed share issue of SEK 159m . Ilija Batljan enters as new large shareholder ~ USD 0.4bn ~ USD 0.6bn ~ USD 0.4bn Significant events during the third quarter >>> Results from prospective multicentre study with 5-7 years ' follow - up of the first Swedish Episealer® Knee patients accepted for publication >> Results from first comparative study with the Episealer® Knee implant were accepted for publication Episurf Medical investigates the opportunities for launching an implant for the MTP joint in the US market Episurf Medical announced additions to the European sales force and Patrick Jamnik to head US business >>> Episurf Medical provided an update on the project Episealer® Patellofemoral System for the US market >>> Episealer® Talus : Case report with 5 - years ' follow - up data were accepted for publication >> European multicentre study were initiated for 5 years ' follow - up of Episealer® Talus patients